Laboratory of Molecular Biology, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland 20892-0560.
Department of Microbiology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania.
Microbiol Spectr. 2014 Dec;2(6). doi: 10.1128/microbiolspec.MDNA3-0026-2014.
In order to replicate, a retrovirus must integrate a DNA copy of the viral RNA genome into a chromosome of the host cell. The study of retroviral integration has advanced considerably in the past few years. Here we focus on host factor interactions and the linked area of integration targeting. Genome-wide screens for cellular factors affecting HIV replication have identified a series of host cell proteins that may mediate subcellular trafficking for preintegration complexes, nuclear import, and integration target site selection. The cell transcriptional co-activator protein LEDGF/p75 has been identified as a tethering factor important for HIV integration, and recently, BET proteins (Brd2, 4, and 4) have been identified as tethering factors for the gammaretroviruses. A new class of HIV inhibitors has been developed targeting the HIV-1 IN-LEDGF binding site, though surprisingly these inhibitors appear to block assembly late during replication and do not act at the integration step. Going forward, genome-wide studies of HIV-host interactions offer many new starting points to investigate HIV replication and identify potential new inhibitor targets.
为了进行复制,逆转录病毒必须将病毒 RNA 基因组的 DNA 拷贝整合到宿主细胞的染色体中。在过去的几年中,逆转录病毒整合的研究已经取得了相当大的进展。在这里,我们关注宿主因子相互作用和相关的整合靶向区域。对影响 HIV 复制的细胞因子进行全基因组筛选,鉴定出一系列宿主细胞蛋白,这些蛋白可能介导整合前复合物的亚细胞运输、核输入和整合靶位选择。细胞转录共激活蛋白 LEDGF/p75 已被鉴定为 HIV 整合的重要固定因子,最近,BET 蛋白(Brd2、4 和 4)已被鉴定为γ逆转录病毒的固定因子。已经开发出一类针对 HIV-1 IN-LEDGF 结合位点的新型 HIV 抑制剂,尽管令人惊讶的是,这些抑制剂似乎在复制后期阻止组装,而不在整合步骤发挥作用。展望未来,对 HIV-宿主相互作用的全基因组研究为研究 HIV 复制和鉴定潜在的新抑制剂靶标提供了许多新的起点。